Literature DB >> 24519546

RIPK4 is downregulated in poorly differentiated tongue cancer and is associated with migration/invasion and cisplatin-induced apoptosis.

Xinhua Wang1, Wenyuan Zhu, Yi Zhou, Wanlian Xu, Huiming Wang.   

Abstract

BACKGROUND: RIPK4 is essential for the identification of keratinocyte differentiation and cutaneous inflammation. The mechanisms involved in the tumorigenesis of tongue squamous cell carcinoma (TSCC) have not been well characterized yet.
OBJECTIVE: To assess RIPK4 expression in various differentiated TSCC and to determine its basic biological function.
METHODS: Overall, 109 human samples (36 normal tongue tissues and 73 surgically excised TSCC tissues with different degrees of differentiation) were collected for the present study. The expression of RIPK4 was assessed by real time PCR and immunocytochemistry. Multivariate logistic regression analysis was used to investigate the association between RIPK4 and clinical characteristics. In vitro analyses by scratch wound healing assay and invasion assays, as well as confocal laser scanning microscopy and flow cytometry analysis were performed using the Tca-8113 tongue cancer cell line. Cisplatin sensitivity analysis and cisplatin-induced activation of caspase 8 analysis were also performed.
RESULTS: A significantly higher level of RIPK4 was found in well-differentiated TSCC samples than in the poorly differentiated ones (p<0.01). Male patients had relatively higher levels of RIPK4 (p=0.03). RIPK4 levels were also increased in older patients. In vitro, RIPK4 reduced the migration and invasion of the Tca-8113 cell line, but did not affect apoptosis and cell cycle. Both RIPK4 up or downregulation induced cell sensitivity to cisplatin, determining cell apoptosis.
CONCLUSIONS: In the present work we found a correlation between RIPK4 expression and TSCC degree of differentiation, age, and gender. The better understanding of the molecular mechanism of RIPK4 in TSCC may provide a promising biomarker for tongue cancer prognosis and treatment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24519546     DOI: 10.5301/jbm.5000073

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   2.659


  13 in total

1.  PKK deletion in basal keratinocytes promotes tumorigenesis after chemical carcinogenesis.

Authors:  Luojing Chen; Matthew S Hayden; Elaine S Gilmore; Carolina Alexander-Savino; David Oleksyn; Kathleen Gillespie; Jiyong Zhao; Brian Poligone
Journal:  Carcinogenesis       Date:  2018-03-08       Impact factor: 4.944

2.  Increased RIPK4 expression is associated with progression and poor prognosis in cervical squamous cell carcinoma patients.

Authors:  De-Qing Liu; Fang-Fang Li; Jiang-Bo Zhang; Tie-Jun Zhou; Wen-Qiong Xue; Xiao-Hui Zheng; Yuan-Bin Chen; Xiao-Yu Liao; Lan Zhang; Shao-Dan Zhang; Ye-Zhu Hu; Wei-Hua Jia
Journal:  Sci Rep       Date:  2015-07-07       Impact factor: 4.379

3.  RIP4 inhibits STAT3 signaling to sustain lung adenocarcinoma differentiation.

Authors:  Jawahar Kopparam; Johanna Chiffelle; Paolo Angelino; Alessandra Piersigilli; Nadine Zangger; Mauro Delorenzi; Etienne Meylan
Journal:  Cell Death Differ       Date:  2017-06-02       Impact factor: 15.828

4.  RIPK4/PEBP1 axis promotes pancreatic cancer cell migration and invasion by activating RAF1/MEK/ERK signaling.

Authors:  Zi-Hao Qi; Hua-Xiang Xu; Shi-Rong Zhang; Jin-Zhi Xu; Shuo Li; He-Li Gao; Wei Jin; Wen-Quan Wang; Chun-Tao Wu; Quan-Xing Ni; Xian-Jun Yu; Liang Liu
Journal:  Int J Oncol       Date:  2018-02-07       Impact factor: 5.650

Review 5.  Protein Hydroxylation by Hypoxia-Inducible Factor (HIF) Hydroxylases: Unique or Ubiquitous?

Authors:  Moritz J Strowitzki; Eoin P Cummins; Cormac T Taylor
Journal:  Cells       Date:  2019-04-26       Impact factor: 6.600

6.  Silencing of RIPK4 inhibits epithelial‑mesenchymal transition by inactivating the Wnt/β‑catenin signaling pathway in osteosarcoma.

Authors:  Zhigang Yi; Yanchuan Pu; Ruoyan Gou; Yonggang Chen; Xiaojun Ren; Wenzhong Liu; Ping Dong
Journal:  Mol Med Rep       Date:  2020-01-14       Impact factor: 2.952

7.  Downregulation of RIPK4 Expression Inhibits Epithelial-Mesenchymal Transition in Ovarian Cancer through IL-6.

Authors:  Huan Yi; Yan-Zhao Su; Rong Lin; Xiang-Qin Zheng; Diling Pan; Dan-Mei Lin; Xiang Gao; Rong Zhang
Journal:  J Immunol Res       Date:  2021-03-26       Impact factor: 4.818

8.  RIPK4 Suppresses the Invasion and Metastasis of Hepatocellular Carcinoma by Inhibiting the Phosphorylation of STAT3.

Authors:  Haoran Li; Dingan Luo; Lakshmi Huttad; Mao Zhang; Youpeng Wang; Juan Feng; Yunfeng Ding; Bing Han
Journal:  Front Mol Biosci       Date:  2021-06-18

9.  PKK suppresses tumor growth and is decreased in squamous cell carcinoma of the skin.

Authors:  Brian Poligone; Elaine S Gilmore; Carolina V Alexander; David Oleksyn; Kathleen Gillespie; Jiyong Zhao; Sherrif F Ibrahim; Alice P Pentland; Marc D Brown; Luojing Chen
Journal:  J Invest Dermatol       Date:  2014-10-06       Impact factor: 8.551

10.  RIPK4 promotes bladder urothelial carcinoma cell aggressiveness by upregulating VEGF-A through the NF-κB pathway.

Authors:  Jian-Ye Liu; Qing-Hai Zeng; Pei-Guo Cao; Dan Xie; Xin Chen; Fei Yang; Le-Ye He; Ying-Bo Dai; Jing-Jing Li; Xiao-Ming Liu; Hong-Liang Zeng; Yi-Xin Zhu; Lian Gong; Yan Cheng; Jian-Da Zhou; Jun Hu; Hao Bo; Zhen-Zhou Xu; Ke Cao
Journal:  Br J Cancer       Date:  2018-06-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.